Cargando…

Epigenetics in Liver Fibrosis: Could HDACs be a Therapeutic Target?

Chronic liver diseases (CLD) represent a worldwide health problem. While CLDs may have diverse etiologies, a common pathogenic denominator is the presence of liver fibrosis. Cirrhosis, the end-stage of CLD, is characterized by extensive fibrosis and is markedly associated with the development of hep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Claveria-Cabello, Alex, Colyn, Leticia, Arechederra, Maria, Urman, Jesus M., Berasain, Carmen, Avila, Matias A., Fernandez-Barrena, Maite G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589994/ https://www.ncbi.nlm.nih.gov/pubmed/33086678 http://dx.doi.org/10.3390/cells9102321

Ejemplares similares

Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg
por: Fernández-Barrena, Maite G., et al.
Publicado: (2020)

Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis
por: Claveria-Cabello, Alex, et al.
Publicado: (2020)

Epigenetic Biomarkers for the Diagnosis and Treatment of Liver Disease
por: Arechederra, María, et al.
Publicado: (2021)

Epigenetic Mechanisms in Gastric Cancer: Potential New Therapeutic Opportunities
por: Canale, Matteo, et al.
Publicado: (2020)

SLU7: A New Hub of Gene Expression Regulation—From Epigenetics to Protein Stability in Health and Disease
por: Gárate-Rascón, María, et al.
Publicado: (2022)

Comprehensive analysis of epigenetic and epitranscriptomic genes’ expression in human NAFLD
por: Herranz, Jose M., et al.
Publicado: (2023)

Epigenetic Mechanisms in Hepatic Stellate Cell Activation During Liver Fibrosis and Carcinogenesis
por: Barcena-Varela, Marina, et al.
Publicado: (2019)

Liquid biopsy for cancer management: a revolutionary but still limited new tool for precision medicine
por: Arechederra, María, et al.
Publicado: (2020)

La biopsia líquida en el manejo del cáncer: una nueva herramienta revolucionaria de la medicina de precisión, aún con limitaciones
por: Arechederra, María, et al.
Publicado: (2020)

Splicing events in the control of genome integrity: role of SLU7 and truncated SRSF3 proteins
por: Jiménez, Maddalen, et al.
Publicado: (2019)

The splicing regulator SLU7 is required to preserve DNMT1 protein stability and DNA methylation
por: Recalde, Miriam, et al.
Publicado: (2021)

HIF2α Activation in NASH: A New Force Pushing Toward HCC
por: Clavería-Cabello, Alex, et al.
Publicado: (2021)

DNA Methylation Regulates a Set of Long Non-Coding RNAs Compromising Hepatic Identity during Hepatocarcinogenesis
por: Recalde, Miriam, et al.
Publicado: (2022)

New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming
por: Colyn, Leticia, et al.
Publicado: (2022)

Activation of the Unfolded Protein Response (UPR) Is Associated with Cholangiocellular Injury, Fibrosis and Carcinogenesis in an Experimental Model of Fibropolycystic Liver Disease
por: Chen, Chaobo, et al.
Publicado: (2021)

Oral Methylthioadenosine Administration Attenuates Fibrosis and Chronic Liver Disease Progression in Mdr2−/− Mice
por: Latasa, M. Ujue, et al.
Publicado: (2010)

Epigenetic remodelling in human hepatocellular carcinoma
por: Braghini, Maria Rita, et al.
Publicado: (2022)

New mechanisms involving the EGFR and FGF15/19 systems in liver regeneration and carcinogenesis
por: Berasain, Carmen, et al.
Publicado: (2014)

Targeting CCL2/CCR2 in Tumor-Infiltrating Macrophages: A Tool Emerging Out of the Box Against Hepatocellular Carcinoma
por: Avila, Matías A., et al.
Publicado: (2018)

Vitamin A in Nonalcoholic Fatty Liver Disease: A Key Player in an Offside Position?
por: Berasain, Carmen, et al.
Publicado: (2020)

Pilot Multi-Omic Analysis of Human Bile from Benign and Malignant Biliary Strictures: A Machine-Learning Approach
por: Urman, Jesús M., et al.
Publicado: (2020)

HDAC Inhibitors: Therapeutic Potential in Fibrosis-Associated Human Diseases
por: Yoon, Somy, et al.
Publicado: (2019)

Engineered fibroblast growth factor 19 protects from acetaminophen-induced liver injury and stimulates aged liver regeneration in mice
por: Alvarez-Sola, Gloria, et al.
Publicado: (2017)

Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures
por: Arechederra, Maria, et al.
Publicado: (2022)

MiR-873-5p acts as an epigenetic regulator in early stages of liver fibrosis and cirrhosis
por: Fernández-Ramos, David, et al.
Publicado: (2018)

Fragile X mental retardation protein in intrahepatic cholangiocarcinoma: regulating the cancer cell behavior plasticity at the leading edge
por: Carotti, Simone, et al.
Publicado: (2021)

HOXD8 hypermethylation as a fully sensitive and specific biomarker for biliary tract cancer detectable in tissue and bile samples
por: Loi, Eleonora, et al.
Publicado: (2022)

Cardiotrophin-1 defends the liver against ischemia-reperfusion injury and mediates the protective effect of ischemic preconditioning
por: Iñiguez, Maria, et al.
Publicado: (2006)

Epigenetics in Brain Tumors: HDACs Take Center Stage
por: Eyüpoglu, Ilker Y., et al.
Publicado: (2016)

Short communication: TNF-α and IGF-1 regulates epigenetic mechanisms of HDAC2 and HDAC10
por: Jiang, Wanlin, et al.
Publicado: (2022)

Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors
por: Thomas, Elizabeth A.
Publicado: (2014)

HDAC inhibitors in experimental liver and kidney fibrosis
por: Van Beneden, Katrien, et al.
Publicado: (2013)

Food Bioactive HDAC Inhibitors in the Epigenetic Regulation of Heart Failure
por: Evans, Levi W., et al.
Publicado: (2018)

Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer
por: Berasain, Carmen, et al.
Publicado: (2011)

Impact of CYLD on chromatin structure and histone methylation in malignant melanoma
por: Schott, Mandy, et al.
Publicado: (2022)

HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis
por: Lyu, Xing, et al.
Publicado: (2019)

HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer
por: Mayr, Christian, et al.
Publicado: (2021)

The TGF-β Pathway: A Pharmacological Target in Hepatocellular Carcinoma?
por: Gonzalez-Sanchez, Ester, et al.
Publicado: (2021)

Drug inhibition of HDAC3 and epigenetic control of differentiation in Apicomplexa parasites
por: Bougdour, Alexandre, et al.
Publicado: (2009)

HDAC mediated suppression of histone turnover promotes epigenetic stability of heterochromatin
por: Aygün, Ozan, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_e9iqc9sctj497mb8pbtk4i1irm